Is Sai Life Sciences Overvalued or Undervalued Right Now?
- September 2, 2026
- Posted by: Lakshit Sharma
- Category: Market
Sai Life Sciences CMP Rs 1,559.60 (2 Sep 2026), up 2.73%. PE 89.14 vs industry PE 38.05. ROE 14.05%. 52W range Rs 783.85 to Rs 1,561.55.
Quick Answer
Sai Life Sciences trades at a price to earnings ratio of 89.14, 2.34 times the industry average of 38.05, which points toward overvaluation on a simple multiple basis. The company backs part of that premium with a 14.05% return on equity and a book value of Rs 116.98 per share. Whether Sai Life Sciences is overvalued or undervalued right now depends on how much an investor is willing to pay for that level of quality and consistency. On valuation multiples alone, the stock currently sits well above what the broader sector is priced at.
Is Sai Life Sciences overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 1,559.60, the stock trades roughly 0.1% below its 52 week high of Rs 1,561.55 and about 99.0% above its 52 week low of Rs 783.85.
Sai Life Sciences’s share price moved up 2.73% in the latest session to Rs 1,559.60, against a market capitalisation of Rs 32,248 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple, and works through the full Sai Life Sciences overvalued or undervalued picture step by step.
Click Here – Get Free Investment Predictions
Sai Life Sciences Overvalued or Undervalued: Valuation Metrics
| Valuation Metric | Sai Life Sciences |
|---|---|
| CMP (2 Sep 2026) | Rs 1,559.60 |
| Market Cap | Rs 32,248 Cr |
| P/E Ratio | 89.14 |
| Industry P/E | 38.05 |
| P/B Ratio | 12.98 |
| Sector Average P/B (pharmaceutical) | 7.31 |
| Return on Equity (ROE) | 14.05% |
| Sector Average ROE (pharmaceutical) | 12.94% |
| EPS (TTM) | Rs 17.04 |
| Book Value per Share | Rs 116.98 |
| Debt to Equity | 0.12 |
| Dividend Yield | 0.00% |
| Sector Average Dividend Yield (pharmaceutical) | 0.30% |
| 52 Week High / Low | Rs 1,561.55 / Rs 783.85 |
The headline number here is the price to earnings ratio. At 89.14, the Sai Life Sciences PE ratio is 2.34 times the industry average of 38.05. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P/B of 12.98 against a sector average of 7.31, and an ROE of 14.05% against a sector average of 12.94%. This table alone is not enough to settle whether Sai Life Sciences overvalued or undervalued is the fair read, but it is the starting point for the rest of this analysis.
Is Sai Life Sciences Overvalued or Undervalued Based on Its P/E Ratio?
Based on the P/E ratio alone, Sai Life Sciences looks overvalued. The stock’s PE of 89.14 is well above the industry average of 38.05, and a multiple this wide over the sector typically prices in years of above average growth and near flawless execution. Investors relying only on the PE ratio would classify Sai Life Sciences as expensive relative to peers, even though the underlying business quality helps explain part of the gap. The Sai Life Sciences PE ratio needs to be read alongside its return ratios rather than in isolation before calling Sai Life Sciences overvalued or undervalued on this measure alone.
Check Sai Life Sciences’s Live Fundamentals on the Univest Screener
Sai Life Sciences’s Financial Growth and Profitability
Sai Life Sciences’s revenue moved from Rs 1,731.35 crore in FY2025 to Rs 2,241.62 crore in FY2026, a change of 29.5%. Net profit grew from Rs 170.13 crore to Rs 348.91 crore over the same period, a swing of roughly 105.1%.
The Sai Life Sciences share price has moved alongside this earnings trend, which is part of why the stock now trades at 2.34 times the industry PE of 38.05 rather than a flat multiple.
These growth numbers feed directly into the Sai Life Sciences overvalued or undervalued question, since a rich multiple is easier to justify when profit growth is accelerating than when it is flat or falling.
Download the Univest iOS App or Univest Android App to track Sai Life Sciences’s live share price and valuation ratios.
Sai Life Sciences Overvalued or Undervalued: The Case for Overvalued
Before getting to the bullet points, it helps to frame the Sai Life Sciences overvalued or undervalued question in terms of what would make the bear case right.
- Valuation premium: The stock’s PE of 89.14 is 2.34 times the industry average of 38.05.
- Rich price to book: A P/B of 12.98 is well above the sector average of 7.31.
- Low dividend yield: At 0.00%, the stock offers little income cushion if the growth story slows.
Sai Life Sciences Overvalued or Undervalued: The Case Against It
The other side of the Sai Life Sciences overvalued or undervalued debate rests on the quality metrics below.
- Low leverage: A debt to equity ratio of 0.12 gives Sai Life Sciences a comparatively strong balance sheet.
- 52 week range context: At Rs 1,559.60, the stock is 99.0% above its 52 week low of Rs 783.85, showing it has already found some support at lower levels.
Verdict: Is Sai Life Sciences Overvalued or Undervalued Right Now?
On balance, Sai Life Sciences looks overvalued by traditional multiples. Its PE of 89.14 is difficult to defend on relative valuation grounds alone, and a reversion toward the industry average PE of 38.05 would imply real downside from the current price of Rs 1,559.60. At the same time, a 14.05% ROE and the other quality metrics above are the kind of numbers that have historically supported premium multiples for well run businesses in India. Investors who already hold the stock may find the fundamentals reassuring, while those looking to enter fresh would be taking on valuation risk at current levels. On the specific question of Sai Life Sciences overvalued or undervalued, the multiples currently point one way even if the fundamentals soften that read.
What Could Change Whether Sai Life Sciences Is Overvalued or Undervalued?
Two broad scenarios could shift this valuation call on Sai Life Sciences in either direction. On the upside, a sustained acceleration in revenue and profit growth that lets earnings catch up to the current PE of 89.14, rather than the price correcting down to the industry average. On the downside, a slowdown in growth or margins, which would leave the stock reliant on a PE de-rating toward the industry average of 38.05 to restore a more typical valuation. Investors watching the Sai Life Sciences share price over the next few quarters should track whether reported ROE holds near 14.05% and whether the PE gap versus the industry average of 38.05 widens or narrows, since both will matter more to the eventual answer on Sai Life Sciences overvalued or undervalued than the current price point on its own.
Conclusion
Sai Life Sciences’s numbers point to a stock that is overvalued on headline multiples, though its return ratios help explain part of the gap. Investors tracking the Sai Life Sciences share price should watch whether earnings growth can keep pace with the current PE of 89.14, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. For anyone still weighing Sai Life Sciences overvalued or undervalued as a one-line takeaway, the multiples say overvalued while the return ratios offer partial support for the current price. This article is for informational purposes only and is not investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Sai Life Sciences Overvalued or Undervalued: FAQs
Is Sai Life Sciences overvalued or undervalued right now?
Ans. Based on a PE ratio of 89.14 against an industry average of 38.05, Sai Life Sciences currently looks overvalued on relative valuation. Its 14.05% ROE is an important part of the Sai Life Sciences overvalued or undervalued picture alongside the PE ratio.
What is Sai Life Sciences’s current PE ratio?
Ans. Sai Life Sciences’s price to earnings ratio stands at 89.14, compared with an industry average PE of 38.05. This PE gap is the main input into the Sai Life Sciences overvalued or undervalued call made in this article.
What is Sai Life Sciences’s return on equity?
Ans. Sai Life Sciences generates a return on equity of 14.05%, against a sector average of 12.94% among pharmaceutical peers.
What is Sai Life Sciences’s 52 week high and low?
Ans. Sai Life Sciences’s 52 week high is Rs 1,561.55 and its 52 week low is Rs 783.85. The stock currently trades around Rs 1,559.60, roughly 0.1% below its high.
Does Sai Life Sciences have high debt?
Ans. Sai Life Sciences carries a debt to equity ratio of 0.12, which is low for its sector.
What is Sai Life Sciences’s dividend yield?
Ans. Sai Life Sciences offers a dividend yield of 0.00% at the current share price.
Is Sai Life Sciences a good stock to buy at current levels?
Ans. Sai Life Sciences’s current valuation suits investors who agree with the overvalued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.
What is Sai Life Sciences’s price to book ratio?
Ans. Sai Life Sciences trades at a price to book ratio of 12.98, compared with a sector average of 7.31 among pharmaceutical peers.
What is the simplest way to summarise Sai Life Sciences overvalued or undervalued?
Ans. On PE alone, Sai Life Sciences is overvalued against its industry average of 38.05. Layer in the 14.05% ROE and the answer to Sai Life Sciences overvalued or undervalued becomes more nuanced than the headline multiple suggests on its own.